Publications and communications of Beguin, Yves

Book chapters as author or co-author

GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc.

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.

Beguin, Y. (2008). Erythropoiesis. In C. Gasche, Anemia in inflammatory bowel disease (pp. 38-42). Uni-Med Verlag.

Beguin, Y., & Estatiev, R. (2008). Iron deficiency. In C. Gasche, Anemia in inflammatory bowel disease (pp. 42-47). Uni-Med Verlag.

Beguin, Y., & Vanstraelen, G. (2008). Prediction of response to recombinant human erythropoietin in the anemia of cancer. In M. R. Nowrousian, Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.). Berlin - Heidelberg, Germany: Springer-Verlag.

Vanstraelen, G., & Beguin, Y. (2008). rhEPO in hematopoietic stem cell transplantation. In M. R. Nowrousian, Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (pp. 583-614). Berlin - Heidelberg, Germany: Springer-Verla.

Beguin, Y., Dujardin, C., Piron, M., & Vanstraelen, G. (2006). Treatment of anaemia with erythropoietin. In C. Brugnara & C. Beaumont, ESH Scientific Updates. Disorders of Iron Homeostasis, Erythrocytes and erythropoiesis (pp. 180-209). Elsevier Science.

Beguin, Y. (2005). Erythropoietic agents and iron. In M. Aapro, C. Bokemeyer, & H. Ludwig, ESO Scientific Updates, Vol. 6 (2nd ed). Anaemia in cancer (pp. 199-220). Elsevier Science.

Beguin, Y. (2005). Endogenous erythropoietin in the anemia of chronic disorders. In W. Weiss, V. R. Gordeuk, & C. Hershko, Anemia of chronic disease (pp. 145-200). New York, United States - New York: Marcel Dekker.

Beguin, Y. (2002). Predictive factors for response of anemia to recombinant human erythropoietin. In M. R. Nowrousian, Recombinant human erythropoietin (rhEPO) in clinical oncology (pp. 263-286). Berlin - Heidelberg, Germany: Springer-Verlag.

Beguin, Y. (2001). Prediction of response to rHuEpo. In C. Bokemeyer & H. Ludwig, ESO Scientific Upadtes, Vol. 6 Anaemia in cancer (pp. 153-165). Elsevier Science.

Clement, J., De Bock, R., & Beguin, Y. (1994). Defective Epo production contributes to anemia persistent after ARF in nephropathia epidemica (NE). In Papadimitriou & Alexopoulos, Proceedings of the 3rd International Satellite Symposium on Acute Renal Failure (pp. 467-473). Thessaloniki, Greece: University Studio Press.

Baudoux, E., Janssens, M., Beguin, Y., Sondag, D., Fillet, G., & Lamy, M. (1993). Erythropoietin in surgery. In Proceedings of the 4th Regional Congress of the International Society of Blood Transfusion (pp. 213-217).

Fillet, G., & Beguin, Y. (1992). Iron availability for erythropoiesis. In C. Drewienkiewicz, The potential use of erythropoietin to diminish the need for homologous blood in surgery (pp. 43-49). Medical Action Communication.

Beguin, Y., Huebers, H., Finch, C. A., Weber, G., & Roelandts, I. (1988). The regulation of liver iron metabolism. In P. Bratter & P. Schramel, Trace element analytical chemistry in medicine and biology, Vol. 5 (pp. 542-547). Walter de Gruyter.

Beguin, Y., Weber, G., Delbrouck, J.-M., Robaye, G., Roelandts, I., Bury, J., & Fillet, G. (1987). Dosage du zinc sérique chez des patients atteints de leucémie aiguë. In A. Favier, J. Arnaud, & H. Faure, Le zinc en médecine et biologie (pp. 224-226). Paris, France: Editions Médicales Internationales.

Beguin, Y., Detroz, B., Defraigne, J.-O., Bury, J., Boniver, J., Fillet, G., & Lejeune, G. (1985). Solitary plasmacytoma of the thyroid with serum monoclonal IgG. In J. Radl, W. Hijmans, & B. Van Camp, Monoclonal gammopathies. Clinical significance and basic mechanisms (pp. 251-253). Eurage.

Beguin, Y., Delbrouck, J.-M., Roelandts, I., & Weber, G. (1984). Serum trace elements in hemoproliferative diseases. In P. Bratter & P. Schramel, Trace element analytical chemistry in medicine and biology, Vol. 3 (pp. 383-389). Walter de Gruyter.

Articles accepted in peer reviewed journal

HUYNEN, P.* , GREGOIRE, C.* , GOFFLOT, S., SEIDEL, L., MAES, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (25 March 2022). Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12 (1), 5156. doi:10.1038/s41598-022-09215-8

BARON, F., Canti, L., Ariën, K. K., Kemlin, D., Desombere, I., Gerbaux, M., Pannus, P., BEGUIN, Y., Marchant, A., & Humblet-Baron, S. (2022). Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Frontiers in Immunology, 13, 827242. doi:10.3389/fimmu.2022.827242

Poiré, X., Graux, C., ORY, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachée, P., Selleslag, D., & Beguin, Y. (2022). Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57, 116-118. doi:10.1038/s41409-021-01464-x

VANDERMEULEN, M., Mohamed Wais, M., DELBOUILLE, M.-H., MAGGIPINTO, G., BEGUIN, Y., & DETRY, O. (August 2021). Long term follow-up of liver transplant recipients after allogeneic mesenchymal stromal cell infusion. Transplant International, 34 (S1 OP282), 45.

Bay, J. O., Beguin, Y., CARPENTIER, A., Dard, C., Guillaume, T., Labussiere-Wallet, H., Lacassagne, M. N., Sauze, S., Yakoub-Agha, I., & Chalandon, Y. (2021). Comment faire face à un évènement inattendu pouvant modifier l’activité normale de thérapie cellulaire? Recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bulletin du Cancer, 108, 20-S25. doi:10.1016/j.bulcan.2021.05.002

BEGUIN, Y. (2021). L’Institut de Cancérologie Arsène Burny (ICAB) et son nouveau bâtiment du Centre Intégré d’Oncologie (CIO) au CHU de Liège. Revue Médicale de Liège, 76, 300-306.

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

DE VOEGHT, A., JASPERS, A., BEGUIN, Y., Baron, F., & DE PRIJCK, B. (2021). Principes généraux de la prise en charges des leucémies aiguës de l’adulte en 2021 en Belgique. Revue Médicale de Liège, 76, 470-475.

Duray, E., Lejeune, M., Baron, F., Beguin, Y., Devoogdt, N., Krasniqi, A., Lauwers, Y., Zhao, Y. J., D'Huyvetter, M., Dumoulin, M., & Caers, J. (2021). A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of hematology & oncology, 14 (1), 183. doi:10.1186/s13045-021-01171-6

Ehx, G., Ritacco, C., HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505

Janssens, A., Selleslag, D., Depaus, J., BEGUIN, Y., & Lambert, C. (2021). Primary immune thrombocytopenia in adults. Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society. Acta Clinica Belgica, 26, 1-14. doi:10.1080/17843286.2021.1876310

Janssens, A., Selleslag, D., Depaus, J., BEGUIN, Y., & Lambert, C. (2021). Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society. Belgian Journal of Hematology, 12, 112-127.

Kröger, N., Sbianchi, G., Sirait, T., Wolschke, C., Beelen, D., Passweg, J., Robin, M., Vrhovac, R., Helbig, G., Sockel, K., Conneally, E., Rubio, M. T., Beguin, Y., Finke, J., Bernasconi, P., Morozova, E., Clausen, J., von dem Borne, P., Schaap, N., & Yakoub-Agha, I. (2021). Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia, 35, 3551-3580. doi:10.1038/s41375-021-01276-4

LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., & BEGUIN, Y. (2021). MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells, 10, 1320. doi:10.3390/cells10061320

Lejeune, M., Duray, E., Peipp, M., Clémenceau, B., Baron, F., Beguin, Y., & Caers, J. (2021). Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers, 13 (12), 3072. doi:10.3390/cancers13123072

MAQUET, C., BEGUIN, Y., DE PRIJCK, B., WILLEMS, E., SERVAIS, S., & BONNET, C. (2021). Le lymphome diffus à grandes cellules B : nouveau traitement révolutionnaire par des cellules immunitaires génétiquement modifiées appelées «CAR T cells». Revue Médicale de Liège, 76, 476-481.

Miano, M., Eikema, D.-J., de la Fuente, J., Bosman, P., Ghavamzadeh, A., Smiers, F., Sengeløv, H., Yesilipek, A., Formankova, R., Bader, P., Díaz Pérez, M. Á., Bertrand, Y., Niemeyer, C., Diallo, S., Ansari, M., Bykova, T. A., Faraci, M., Bonanomi, S., Gozdzik, J., & Dufour, C. (2021). Stem Cell Transplantation for Diamond-Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). Transplantation and Cellular Therapy, 27 (3), 274.e1-274.e5. doi:10.1016/j.jtct.2020.12.024

Narinx, J., SERVAIS, S., BARON, F., BEGUIN, Y., & WILLEMS, E. (2021). Allogreffes de cellules souches hématopoïétiques : principes généraux et progrès récents. Revue Médicale de Liège, 76, 464-469.

PIROTTE, M., Fillet, M., SEIDEL, L., JASPERS, A., Baron, F., & Beguin, Y. (2021). Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. American Journal of Hematology, 96 (10), 1275-1286. doi:10.1002/ajh.26300

Ritacco, C., Ehx, G., GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0

SCHEEN, A., BEGUIN, Y., & JERUSALEM, G. (2021). L’oncologie, à un tournant de son histoire. Revue Médicale de Liège, 76, 297-299.

The COVID-19 Host Genetics Initiative, Gazon, H., JUSZCZAK, D., FADEUR, M., CAMBY, S., MEURIS, C., THYS, M., JACQUES, J., HENKET, M., BEGUIN, Y., Rahmouni, S., Lebrun, M., MOUTSCHEN, M., Misset, B., DARCIS, G., GUIOT, J., AZARZAR, S., DELLOT, P., GOFFLOT, S., & HUYNEN, P. (Other coll.). (2021). Mapping the human genetic architecture of COVID-19. Nature, 600, 472-477. doi:10.1038/s41586-021-03767-x

Vrancken, L., Lejeune, M., PIROTTE, M., Duray, E., Köse, M. C., BEGUIN, Y., & CAERS, J. (2021). Le myélome multiple : un tour d’horizon des nouveautés dans sa biologie et son traitement. Revue Médicale de Liège, 76, 482-488.

Xhaard, A., Xhaard, C., d'Aveni, M., Salvator, H., Chabi-Charvillat, M.-L., Coman, T., BEGUIN, Y., Chalandon, Y., Poiré, X., Loschi, M., Paillard, C., Bruno, B., Ceballos, P., Dalle, J.-H., Bilger, K., Bay, J.-O., Robin, M., N'Guyen-Quoc, S., & Rubio, M.-T. (2021). Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation : a SFGM-TC multicentre cohort study. British Journal of Haematology, 192, 121-e135. doi:10.1111/bjh.17260

Lejeune, M., Köse, M. C., Duray, E., Einsele, H., Beguin, Y., & Caers, J. (07 May 2020). Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology, 11 (762), 1-20. doi:10.3389/fimmu.2020.00762

Azerad, M.-A., BAYOUDH, F., Weber, T., Minon, J.-M., Ketelsleggers, O., HOYOUX, M., Ren, X., Kaye, O., De Marneffe, N., Fraipont, V., Masset, C., Bouillon, A.-S., JASPERS, A., Tebache, M., D'Hoen, G., Habibi, A., Efira, A., Thachil, J., Deckmyn, H., & BEGUIN, Y. (2020). Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. EJHaem, 1 (jha 2.74), 338-341. doi:10.1002/jha2.74

Dhédin, N., Paillard, C., Dalle, J.-H., Ouachée, M., Buchbinder, N., Brissot, E., BEGUIN, Y., Masouridi-Levrat, S., Yakoub-Agha, I., Bernit, E., & Pondarre, C. (2020). Allogreffe de cellules souches hématopoïétiques dans la drépanocytose de l'enfant et de l'adulte : indications et modalités. Bulletin du Cancer, 107, 925-933. doi:10.1016/j.bulcan.2020.06.003

Dubois, V., Amokrane, K., Beguin, Y., Bruno, B., Chevallier, P., Delbos, F., Devillier, R., Giannoli, C., Guidicelli, G., Harif, M., Loiseau, P., Rouzaire, P.-O., Varlet, P., Yakoub-Agha, I., & Nguyen, S. (2020). Greffe de cellules souches hématopoïétiques haplo-identiques avec cyclophosphamide en post-greffe : comment choisir le meilleur donneur en 2019 ? Recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer, 107 (Suppl. 1), 72-84. doi:10.1016/j.bulcan.2019.07.011

HAUZEUR, J.-P., LECHANTEUR, C., BAUDOUX, E., De Maertelaer, V., Pather, S., Katz, R., Malaise, M., Ino, J., & Beguin, Y. (2020). Did Osteoblastic Cell Therapy Improve the Prognosis of Prefracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial. Clinical Orthopaedics and Related Research, 478, 1307-1315.

Lejeune, M., Köse, M. C., Duray, E., Beguin, Y., & CAERS, J. (2020). Les anticorps bispécifiques ciblant les lymphocytes T dans le myélome multiple. Onco: Revue Multidisciplinaire d'Oncologie, 14 (6), 30-34.

Mamez, A.-C., Dupont, A., Blaise, D., Chavallier, P., Forcade, E., Ceballos, P., Mohty, M., Suarez, F., BEGUIN, Y., Peffault de Latour, R., Rubio, M.-T., Tournilhac, O., & Nguyen, S. (2020). Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Journal of Hematology and Oncology, 13, 56. doi:10.1186/s13045-020-00892-4

Roex, G., Feys, T., BEGUIN, Y., Kerre, T., Poiré, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2020). Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies : An Update of the Pivotal Clinical Trial Center. Pharmaceutics, 12, 194. doi:10.3390/pharmaceutics12020194

Snowden, J. A., Saccardi, R., Orchard, K., Ljungman, P., Duarte, R. F., Labopin, M., McGrath, E., Brook, N., Ruiz de Elvira, C., Gordon, D., Poirel, H. A., Ayuk, F., Beguin, Y., Bonifazi, F., Gratwohl, A., Milpied, N., Moore, J., Passweg, J., Rizzo, J. D., & Putter, H. (2020). Benchmarking of Survival Outcomes following Haematopoietic Stem Cell Transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 55, 681-694. doi:10.1038/s41409-019-0718-7

Antoine-Poirel, H., Vanspauwen, M., Macq, G., De Geyndt, A., Maertens, J., WILLEMS, E., Selleslag, D., Poiré, X., Theunissen, K., Graux, C., Kerre, T., Zachée, P., Meuleman, N., De Becker, A., Verlinden, A., Van Obbergh, F., Schuermans, C., De Wilde, V., JASPERS, A., & Beguin, Y. (2019). Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres. Bone Marrow Transplantation, 54, 1434-1442. doi:10.1038/s41409-019-0458-8

Caulier, A., Drumez, E., Gauthier, J., Robin, M., Blaise, D., Beguin, Y., Michallet, M., Chevallier, P., Bay, J.-O., Vigouroux, S., Desbrosses, Y., Cornillon, J., Nguyen, S., Dauriac, C., de Latour, R. P., Lioure, B., Rohrlich, P.-S., Carré, M., Bourhis, J.-H., & Yakoub-Agha, I. (2019). Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. Current Research in Translational Medicine, 67, 8-15. doi:10.1016/j.retram.2018.08.003

Cremers, E., de Witte, T., de Wreede, L., Eikema, D.-J., Koster, L., van Biezen, A., Finke, J., Socié, G., Beelen, D., Maertens, J., Nagler, A., Kobbe, G., Ziagkos, D., Itälä-Remes, M., Gedde-Dahl, T., Sierra, J., Niederwieser, D., Ljungman, P., Beguin, Y., & Kröger, N. (2019). A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation *. Leukemia and Lymphoma, 60, 2404-2414. doi:10.1080/10428194.2019.1594215

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Engel, N., Rovo, A., Badoglio, M., Labopin, M., Basak, G. W., BEGUIN, Y., Guyotat, D., Ljungman, P., Nagler, A., Schattenberg, A., Schroeder, T., Schroyens, W., Tischer, J., Socie, G., Kolb, H.-J., Tichelli, A., Salooja, N., & Duarte, R. F. (2019). European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. Leukemia, 33, 508-517. doi:10.1038/s41375-018-0218-6

Fayard, A., Daguenet, E., Blaise, D., Chevallier, P., Labussière, H., Berceanu, A., Yakoub-Agha, I., Socié, G., Charbonnier, A., Suarez, F., Huynh, A., Mercier, M., Bulabois, C.-E., Lioure, B., Chantepie, S., Beguin, Y., Bourhis, J.-H., Malfuson, J.-V., Clément, L., & Cornillon, J. (2019). Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplantation, 54, 1586-1594. doi:10.1038/s41409-019-0475-7

Feyx, T., Roex, G., Beguin, Y., Kerre, T., Poiré, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2019). Chimeric antigen receptor T-cells: a new therapeutic option for relapsed/refractory B-cell malignancies and beyond. Belgian Journal of Hematology, 10, 301-310.

Fitzgerald, S. P., Grote Beverborg, N., Beguin, Y., Artunc, F., Falhammar, H., & Bean, N. G. (2019). Population data provide evidence against the presence of a set point for hemoglobin levels or tissue oxygen delivery. Physiological Reports, 7 (12), 14153. doi:10.14814/phy2.14153

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Jaimes-Albornoz, D., Mannone, L., Nguyen-Quoc, S., Chalandon, Y., Chevallier, P., Mohty, M., Meunier, M., Robin, M., Ledoux, M.-P., Guillerm, G., Bay, J.-O., Poiré, X., Maillard, N., Leclerc, M., Daguindau, E., Beguin, Y., Rubio, M. T., & Gyan, E. (2019). Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 25, 2366-2374. doi:10.1016/j.bbmt.2019.07.013

JASPERS, A., & Beguin, Y. (2019). Erythropoiesis and iron metabolism after hematopoietic stem cell transplantation. Belgian Journal of Hematology, 10, 89-95.

Muller, J., Duray, E., Lejeune, M., DUBOIS, S., Plougonven, E., Léonard, A., Storti, P., Giuliani, N., Cohen-Solal, M., Hempel, U., Thijssen, V., BEGUIN, Y., Heusschen, R., & CAERS, J. (2019). Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts. Cancers, 11 (2), 261. doi:10.3390/cancers11020261

Nagler, A., Labopin, M., Dholaria, B., Niittyvuopio, R., Maertens, J., Poiré, X., Cornelissen, J., Reményi, P., Bourhis, J. H., Beguin, Y., Malladi, R., Kerre, T., Schroyens, W., Savani, B. N., & Mohty, M. (2019). Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. Blood Advances, 3 (13), 1950-1960. doi:10.1182/bloodadvances.2019000030

WITHOFS, N., Beguin, Y., COUSIN, F., Tancredi, T., SIMONI, P., Alvarez-Miezentseva, V., DE PRIJCK, B., HAFRAOUI, K., Bonnet, C., Baron, F., Hustinx, R., & Caers, J. (2019). Dual-tracer PET/CT scan after injection of combined [ 18 F]NaF and [ 18 F]FDG outperforms MRI in the detection of myeloma lesions. Hematological Oncology, 37, 193-201. doi:10.1002/hon.2600

Zephir, H., Puyade, M., Gueguen, A., Michel, L., Terriou, L., Dive, D., Laureys, G., Mathey, G., Labauge, P., Marjanovic, Z., Pugnet, G., Badoglio, M., Lansiaux, P., Ibrahim, Y.-A., Beguin, Y., & Farge, D. (2019). Indications de l'autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques. Bulletin du Cancer, 106 (Suppl. 1), 92-101. doi:10.1016/j.bulcan.2018.11.002

Farhat, K., Bodart, G., Charlet-Renard, J. D. C., Desmet, C., Moutschen, M., Beguin, Y., Baron, F., Melin, P., Quatresooz, P., Parent, A.-S., Desmecht, D., Sirard, J.-C., Salvatori, R., Martens, H., & Geenen, V. (02 October 2018). Growth hormone (GH) deficient mice with GHRH ablation are severely deficient in vaccine and immune responses against Streptococcus pneumoniae. Frontiers in Immunology, 9, 2175. doi:10.3389/fimmu.2018.02175

Aapro, M. S., Beguin, Y., Bokemeyer, C., Dicato, M., Gascon, P., Glaspy, J. A., Hofmann, A., Link, H., Littlewod, T., Ludwig, H., Osterborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., & Herrstedt, J. (2018). Management of anaemia and iron deficiency in patients with cancer : ESMO Clinical Practice Guidelines. Annals of Oncology, 29, 96-110. doi:10.1093/annonc/mdx758

Akhtar, S., Montoto, S., Boumendil, A., Finel, H., Masszi, T., Jindra, P., Nemet, D., Fuhrmann, S., Beguin, Y., Castagna, L., Ferrara, F., Capria, S., Malladi, R., Moraleda, J. M., Bloor, A., Ghesquières, H., Meissner, J., Sureda, A., & Dreger, P. (2018). High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. American Journal of Hematology, 93 (1), 40-46. doi:10.1002/ajh.24927

Caers, J., Garderet, L., Kortum, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M. A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., & Engelhardt, M. (2018). European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 103, 1172-1184. doi:10.3324/haematol.2018.189159

Decroocq, J., Itzykson, R., Vigouroux, S., Michallet, M., Yakoub-Agha, I., Huynh, A., Beckerich, F., Suarez, F., Chevallier, P., Nguyen-Quoc, S., Ledoux, M.-P., Clement, L., Hicheri, Y., Guillerm, G., Cornillon, J., Contentin, N., Carre, M., Maillard, N., Mercier, M., & Dhedin, N. (2018). Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire. American Journal of Hematology, 93 (3), 416-423. doi:10.1002/ajh.25004

Devos, T., BEGUIN, Y., Noens, L., Van Eygen, K., Zachée, P., Mineur, P., Knoops, L., Doyen, C., Theunissen, K., Benghiat, F. S., Reusens, M., & Pluymers, W. (2018). Disease and treatment characteristics of polycythaemia vera patients in Belgium : results from a scientific survey. European Journal of Haematology, 100, 361-366. doi:10.1111/ejh.13022

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943

Gauthier, J., Poiré, X., Gac, A.-C., Leclerc, M., Guillaume, T., Chalandon, Y., Nguyen, S., Forcade, E., Régny, C., Bay, J.-O., Bazarbachi, A., Rohrlich, P.-S., Huynh, A., Farhi, J., Marchand, T., Malfuson, J.-V., Pilorge, S., Labussière-Wallet, H., Renard, C., & Yakoub-Agha, I. (2018). Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation - A study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 53 (4), 400-409. doi:10.1038/s41409-017-0018-z

HAUZEUR, J.-P., De Maertelaer, V., BAUDOUX, E., MALAISE, M., Beguin, Y., & Gangji, V. (2018). Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial. International Orthopaedics, 42, 1429-1435. doi:10.1007/s00264-017-3650-8

Laureys, G., Willekens, B., Vanopdenbosch, L., Deryck, O., Selleslag, D., D'Haeseleer, M., De Becker, A., Dubois, B., Dierickx, D., Perrotta, G., De Wilde, V., van Pesch, V., Straetmans, N., Dive, D., Beguin, Y., Van Wijmeersch, B., Theunissen, K., Kerre, T., & Van de Velde, A. (2018). A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurologica Belgica, 118 (2), 161-168. doi:10.1007/s13760-018-0905-0

Lewalle, P., & Beguin, Y. (2018). Extracorporeal photochemotherapy for graft versus host disease : Where we are now and where are we going ! Belgian Journal of Hematology, 9, 254-265.

McLornan, D. P., Szydlo, R., Robin, M., van Biezen, A., Koster, L., Blok, H. J. P., Van Lint, M. T., Finke, J., Vitek, A., Carlson, K., Griskevicius, L., Holler, E., Itala-Remes, M., Schaap, M., Socie, G., Bay, J.-O., BEGUIN, Y., Bruno, B., Cornelissen, J. J., & Kroger, N. (2018). Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. British Journal of Haematology, 182, 418-422. doi:10.1111/bjh.15407

Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397

Paviglianiti, A., Tozatto Maio, K., Rocha, V., Gehlkopf, E., Milpied, N., Esquirol, A., Chevallier, P., Blaise, D., Gac, A.-C., Leblond, V., Cahn, J. Y., Abecasis, M., Zuckerman, T., Schouten, H., Gurman, G., Rubio, M. T., Beguin, Y., Corral, L. L., Nagler, A., & Ruggeri, A. (2018). Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biology of Blood and Marrow Transplantation, 24, 2265-2270. doi:10.1016/j.bbmt.2018.07.019

Pirotte, M., Forte, F., Lutteri, L., WILLEMS, E., DURAN, U., Belle, L., Baron, F., BEGUIN, Y., Maquet, P., BODART, O., & Servais, S. (2018). Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Neuroimmunology, 323, 115-118. doi:10.1016/j.jneuroim.2018.08.003

Trento, C., Bernardo, M. E., Nagler, A., Kuçi, S., Bornhäuser, M., Köhl, U., Strunk, D., Galleu, A., Sanchez-Guijo, F., Gaipa, G., Introna, M., Bukauskas, A., Le Blanc, K., Apperley, J., Roelofs, H., Van Campenhout, A., Beguin, Y., Kuball, J., Lazzari, L., & Dazzi, F. (2018). Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 24, 2365-2370. doi:10.1016/j.bbmt.2018.07.015

Van de Velde, A., Willekens, B., Vanopdenbosch, L., Deryck, O., Selleslag, D., D'Haeseleer, M., De Becker, A., Dubois, B., Dierickx, D., Perrotta, G., De Wilde, V., van Pesch, V., Straetmans, N., Dive, D., Beguin, Y., Van Wijmeersch, B., Theunissen, K., Kerre, T., & Laureys, G. (2018). A Belgian consensus protocol for autologous haematopoietic stem cell transplantation in multiple sclerosis. Belgian Journal of Hematology, 9, 167-174.

VANDERMEULEN, M., MAGGIPINTO, G., JOURET, F., BEGUIN, Y., & DETRY, O. (September 2017). DO MESENCHYMAL STROMAL CELLS PROMOTE HLA SPECIFIC ANTIBODIES FORMATION AFTER INFUSION IN LIVER TRANSPLANT RECIPIENTS? Transplant International, 30 (S2), 548 (PLB051.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001

Averbuch, D., Tridello, G., Hoek, J., Mikulska, M., Akan, H., Yaňez San Segundo, L., Pabst, T., Özçelik, T., Klyasova, G., Donnini, I., Wu, D., Gülbas, Z., Zuckerman, T., Botelho De Sousa, A., Beguin, Y., Xhaard, A., Bachy, E., Ljungman, P., De La Camara, R., & Cesaro, S. (2017). Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clinical Infectious Diseases, 65 (11), 1819-1828. doi:10.1093/cid/cix646

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12.

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425

Gauthier, J., Castagna, L., Garnier, F., Guillaume, T., Socié, G., Maury, S., Maillard, N., Tabrizi, R., Marchand, T., Malfuson, J.-V., Gac, A.-C., Gyan, E., Mercier, M., BEGUIN, Y., Delage, J., Turlure, P., Marcais, A., Nguyen, S., Dulery, R., & Blaise, D. (2017). Reduced intensity and non-myeloablative allogenic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin's lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 52, 689-696. doi:10.1038/bmt.2016.34

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864

Heidenreich, S., Ziagkos, D., De Wreede, L., Van Biezen, A., Finke, J., Platzbecker, U., Niederwieser, D., Einsele, H., Bethge, W., Schleuning, M., Beelen, D., Tischer, J., Nagler, A., Glass, B., Maertens, J., Yanez, L., BEGUIN, Y., Sill, H., Scheid, C., & Kröger, N. (2017). Allogeneic stem cell transplantation for patients with myelodysplastic syndrome 70 years of age or older: A retrospective study of the MDS subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. Biology of Blood and Marrow Transplantation, 23, 44-52. doi:10.1016/j.bbmt.2016.09.027

Heusschen, R., Muller, J., WITHOFS, N., BARON, F., BEGUIN, Y., & CAERS, J. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Belgian Journal of Hematology, 8, 66-74.

Libert, Y., Borghgraef, C., Beguin, Y., Delvaux, N., DEVOS, M., Doyen, C., Dubruille, S., Etienne, A.-M., Liénard, A., Merckaert, I., Reynaert, C., Slachmuylder, J.-L., Straetmans, N., Van Den Neste, E., Bron, D., & Razavi, D. (2017). Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study. Psycho-oncology, 26 (12), 2086-2093. doi:10.1002/pon.4424

Libert, Y., Borghgraef, C., BEGUIN, Y., Delvaux, N., DEVOS, M., Doyen, C., Dubruille, S., Etienne, A.-M., Lienard, A., Merckaert, I., Slachmuylder, J., Straetmans, N., Van Den Neste, E., Bron, D., & Razavi, D. (2017). Factors associated with self-perceived burden to the primary caregiver in older patients with hematologic malignancies: an exploratory study. Psycho-oncology, 26, 118-124. doi:10.1002/pon.4108

Magro, L., Forcade, E., Giraud, C., Granata, A., Parquet, N., Rohrlich, P.-S., Terriou, L., Yakoub-Agha, I., & Beguin, Y. (2017). Prise en charge de la maladie du greffon contre l'hôte chronique : Recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer, 104S, 145-S168. doi:10.1016/j.bulcan.2017.10.023

Roth-Guepin, G., Canaani, J., Ruggeri, A., Labopin, M., Finke, J., Cornelissen, J. J., Delage, J., Stuhler, G., Rovira, M., Potter, M., Stadler, M., Veelken, H., Cahn, J. Y., Collin, M., Beguin, Y., Giebel, S., Nagler, A., & Mohty, M. (2017). Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT. Oncotarget, 8 (68), 112972-112979. doi:10.18632/oncotarget.22934

Roux, C., Tifratene, K., Socié, G., Galambrun, C., Bertrand, Y., Rialland, F., Jubert, C., Pochon, C., Paillard, C., Sirvent, A., Nelken, B., Vannier, J.-P., Freycon, C., BEGUIN, Y., Raus, N., Yakoub-Agha, I., Mohty, M., Dalle, J.-H., Michel, G., & Rohrlich, P.-S. (2017). Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplantation, 52, 678-682. doi:10.1038/bmt.2016.360

SERVAIS, S., Hannon, M., Peffault de Latour, R., Socie, G., & BEGUIN, Y. (2017). Reconstitution of adaptive immunity after umbilical cord blood transplantation and clinical implication regarding risk of infections. Stem Cell Investigation, 4, 40.

Sticca, T., CABERG, J.-H., Wenric, S., Poulet, C., HERENS, C., JAMAR, M., Josse, C., El Guendi, S., MAX, S., BEGUIN, Y., GOTHOT, A., CAERS, J., & Bours, V. (2017). Genomic Studies of Multiple Myeloma Reveal an Association between X Chromosome Alterations and Genomic Profile Complexity. Genes, Chromosomes and Cancer, 56, 18-27. doi:10.1002/gcc.22397

Van Obbergh, F., Knoops, L., Devos, T., BEGUIN, Y., Graux, C., Benghiat, S., Kargar-Samani, K., Bauwens, D., Efira, A., Dubois, C., Springael, C., Montfort, L., Connerotte, T., Delannoy, A., & Wallemacq, P. (2017). The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study. Clinical Biochemistry, 50, 452-454. doi:10.1016/j.clinbiochem.2016.12.006

Vrancken, L., Delens, L., BEGUIN, Y., BARON, F., & SERVAIS, S. (2017). Focus sur les lymphocytes T dans la maladie du greffon contre l'hôte après allogreffe de cellules soucges hématopoïétiques: implications pour de nouvelles stratégies de prévention. Onco: Revue Multidisciplinaire d'Oncologie, 11, 23-31.

WITHOFS, N., COUSIN, F., DE PRIJCK, B., Bonnet, C., Hustinx, R., Gambhir, S. S., Beguin, Y., & Caers, J. (2017). A First Report on [(18)F]FPRGD2 PET/CT Imaging in Multiple Myeloma. Contrast Media and Molecular Imaging, 2017, 6162845. doi:10.1155/2017/6162845

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872

Baron, F., & Beguin, Y. (2016). Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time? Bone Marrow Transplantation, 51, 640-42. doi:10.1038/bmt.2016.38

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270

El Cheikh, J., Sfumato, P., Sobh, M., Fegueux, N., Mohty, M., Vigouroux, S., BEGUIN, Y., Yakoub-Agha, I., Socié, G., Cornillon, J., Mercier, M., Bay, J., Blaise, D., Michallet, M., & Peffault de Latour, R. (2016). Allogenic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study for the French society for stem cell transplantation (SFGM-TC). Haematologica, 101, 262-265.

Guièze, R., Damaj, G., Pereira, B., Robin, M., Chevallier, P., Michallet, M., Vigouroux, S., BEGUIN, Y., Blaise, D., Roosweil, D., Thiebaut, A., Rohrlich, P.-S., Huynh, A., Cornillon, J., Contentin, N., Suarez, F., Lioure, B., Mohty, M., Maillard, N., & yakoub-Agha, I. (2016). Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biology of Blood and Marrow Transplantation, 22, 240-247. doi:10.1016/j.bbmt.2015.07.037

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.

JASPERS, A., Bouhya, S., Belaiche, S., Chevallier, P., Hermet, E., Hospital-Gustems, C., Michallet, M., Rialland, F., Samsonova, O., Sirvent, A., Yakoub-Agha, I., Rohrlich, P.-S., & BEGUIN, Y. (2016). Evaluation et prise en charge de la surcharge en fer post-greffe recommandations de la SFGM-TC. Bulletin du Cancer, 103, 255-S266. doi:10.1016/j.bulcan.2016.09.003

LECHANTEUR, C., BRIQUET, A., GIET, O., DELLOYE, O., BAUDOUX, E., & BEGUIN, Y. (2016). Clinical - scale expansion of mesenchymal stromal cells: a large banking experience. Journal of Translational Medicine, 14, 145-159. doi:10.1186/s12967-016-0892-y

Mamez, Levy, V., Chevallier, P., Blaise, D., Vigouroux, S., Xhaard, A., Fegueux, N., Contentin, N., BEGUIN, Y., Ifrah, N., Bulabois, C., Suarez, F., Yakoub-Agha, I., Turlure, P., Deconink, E., Lamy, T., Cahn, J.-Y., Huynh, A., Maury, S., & Nguyen, S. (2016). Effet of immune modulation in relapsed peripheral T-cell lymphomas after allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplantation, 51, 358-364. doi:10.1038/bmt.2015.280

Pirotte, M., GUIOT, J., BEGUIN, Y., & Louis, R. (2016). L'anémie dans la bronchopneumopathie chronique obstructive sévère: une comorbidité plus fréquente que l'on ne croit. Revue Médicale de Liège, 71 (11), 488-494.

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

WEEKERS, L., Erpicum, P., DETRY, O., BONVOISIN, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (2016). administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Transplant International, 29 (Suppl 2), 13 -p6.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., HONORE, P., & BEGUIN, Y. (November 2015). Infusion of third-party mesenchymal stem cells after liver transplantation: a phase-1, open-label, clinical study. Transplant International, 28 (S4), 10/O27.

WEEKERS, L., ERPICUM, P., DETRY, O., JOURET, F., LECHANTEUR, C., DELBOUILLE, M.-H., BRIQUET, A., BAUDOUX, E., & BEGUIN, Y. (November 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. Transplant International, 28 (S4), 223-224/BO278.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

WEEKERS, L., ERPICUM, P., DETRY, O., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (May 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. American Journal of Transplantation, 15 (suppl 3).

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (April 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study. Journal of Hepatology, 62 (S2), 311 (P0052.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (March 2015). Infusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study. Acta Gastro-Enterologica Belgica, 78 (1), 29.

Baron, F., Zachée, P., Maertens, J., Kerre, T., ORY, A., SEIDEL, L., Graux, C., Lewalle, P., Van Gelder, M., Theunissen, K., WILLEMS, E., Emonts, M.-P., De Becker, A., & Beguin, Y. (2015). Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of Hematology and Oncology, 8, 4. doi:10.1186/s13045-014-0098-9

Basak, G., Wiktor-Jedrzejczak, W., Labopin, M., Schoemans, H., Ljungman, P., Kobbe, G., Beguin, Y., Lang, P., Koenecke, C., Sykora, K., te Boome, L., van Biezen, A., van der Werf, S., Mohty, M., de Witte, T., Marsh, J., Dreger, P., Kröger, N., Duarte, R., & Ruutu, T. (2015). Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. American Journal of Transplantation, 15, 705-714. doi:10.1111/ajt.13017

Beguin, Y., Selleslag, D., Meers, S., Graux, C., Bries, G., Deeren, D., Vrelust, I., Ravoet, C., Theunissen, K., Voelter, V., Potier, H., Trullemans, F., Noens, L., & Mineur, P. (2015). Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Acta Clinica Belgica, 70, 34-43. doi:10.1179/2295333714Y.0000000102

Benghiat, F., Beguin, Y., Dessars, B., Devos, T., Lewalle, P., Mineur, P., Straetmans, N., Van Eygen, K., Verhoef, G., & Knoops, L. (2015). Practical management of Chronic Myeloid Leukemia in Belgium. Belgian Journal of Hematology, 6 (1), 16-32.

BONNET, C., Janssens, A., Wu, K., Schroyens, W., Van Hende, V., Heimann, P., Tousseyn, T., André, M., Bron, D., Van Hoof, A., Verhoef, G., DE PRIJCK, B., Beguin, Y., & Dierickx, D. (2015). BHS guidelines for the treatment of Burkitt lymphoma. Belgian Journal of Hematology, 6 (2), 61-69.

Bonnet, C., LEJEUNE, M., VAN KEMSEKE, C., Bron, D., & Beguin, Y. (2015). Prise en charge actuelle du lymphome de la zone marginale. Revue Médicale Suisse, 11, 1549-1556.

Devos, T., Zachée, P., Bron, D., Noens, L., Van Droogenbroeck, J., Mineur, P., Beguin, Y., Berneman, Z., Benghiat, F. S., Kentos, A., Chatelain, C., Demuynck, H., Lemmens, J., Van Eygen, K., Theunissen, K., Trullemans, F., Pierre, P., Pluymers, W., & Knoops, L. (2015). Myelofibrosis patients in Belgium: disease characteristics. Acta Clinica Belgica, 70 (2), 105-111. doi:10.1179/2295333714Y.0000000097

Ehx, G.* , Hannon, M.* , BEGUIN, Y., Humblet-Baron, S.* , & BARON, F.*. (2015). Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget, 6, 43255-43266. doi:10.18632/oncotarget.6486

FOGUENNE, J., SIMUL, M., KEUTGENS, A., TASSIN, F., Bonnet, C., BEGUIN, Y., JAMAR, M., LAMBERT, F., & GOTHOT, A. (2015). Multiparameter flow cytometric analysis of composite lymphoma: case report of a mantle cell lymphoma associated with a B-cell chronic lymphocytic leukemia and an aberrant T cell subset. Belgian Journal of Hematology.

Gauthier, J., Damaj, G., Langlois, C., Robin, M., Michallet, M., Chevallier, P., Beguin, Y., N'guyen, S., Bories, P., Blaise, D., Cornillon, J., Clavert, A., Mohty, M., Huynh, A., Thiébaut-Bertrand, A., Vigouroux, S., Duhamel, A., & Yakoub-Agha, I. (2015). Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the Société Française de Greffe de Moelle et Thérapies Cellulaires. Transplantation, 99 (8), 1672-1680.

Guillaume, T., Beguin, Y., Tabrizi, R., Nguyen, S., Blaise, D., Deconinck, E., Redjoul, R., Cornillon, J., Guillerm, G., Contentin, N., Sirvent, A., Turlure, P., Salmon, A., Huynh, A., Francois, S., Peffault de Latour, R., Yakoub-Agha, I., & Mohty, M. (2015). Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). European Journal of Haematology, 94, 265-269. doi:10.1111/ejh.12430

Halter, J., Michael, W., Schüpbach, W., Mandel, H., Casali, C., Orchard, K., Collin, M., Valcarcel, D., Rovelli, A., Filosto, M., Dotti, M., Marotta, G., Pintos, G., Barba, P., Accarino, A., Ferra, C., Illa, I., Beguin, Y., Bakker, J., & Hirano, M. (2015). Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain: a Journal of Neurology, 138, 2847-2858. doi:10.1093/brain/awv226

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018.

Leclerc, M., Suarez, F., Noël, M.-P., Vekhoff, A., Troussard, X., Claisse, J.-F., Thieblemont, C., Maloisel, F., Beguin, Y., Tamburini, J., Barbe, C., & Delmer, A. (2015). Rituximab therapy for hairy cell leukemia : a retrospective study of 41 cases. Annals of Hematology, 94, 89-95. doi:10.1007/s00277-014-2175-0

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.

Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026

SID, S., Dugauquier, C., DE PRIJCK, B., BONNET, C., & Beguin, Y. (2015). Haemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency. Belgian Journal of Hematology, 6 (2), 74-78.

BEGUIN, Y., ZACHEE, P., MAERTENS, J., KERRE, T., ORY, A., SEIDEL, L., GRAUX, C., LEWALLE, P., VAN GELDER, M., THEUNISSEN, K., WILLEMS, E., EMONDS, M.-P., DE BECKER, A., & BARON, F. (December 2014). Nonmyeloablative allogeneic hematopoietic cell transplantation following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Blood, 124 (21), 542.

DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56.

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

Hannon, M., LECHANTEUR, C., Lucas, S., Somja, J., Seidel, L., Belle, L., Bruck, F., BAUDOUX, E., GIET, O., Chantillon, A.-M., Delvenne, P., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (17 June 2014). Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion, 54 (February), 353-363. doi:10.1111/trf.12279

CAERS, J., HAFRAOUI, K., KEUTGENS, A., CABERG, J.-H., LAMBERT, F., TASSIN, F., & BEGUIN, Y. (02 February 2014). Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide. European Journal of Haematology, 92 (2), 179-180. doi:10.1111/ejh.12233

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

Battisti, O., & Beguin, Y. (2014). A propos de l'encéphalopathie du nouveau-né. Percentile, 19, 8-9.

Beguin, Y., Aapro, M. S., Ludwig, H. P., Mizzen, L., & Osterborg, A. C. (2014). Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis-A critical review. Critical Reviews in Oncology/Hematology, 89, 1-15. doi:10.1016/j.critrevonc.2013.10.008

Beguin, Y., & JASPERS, A. (2014). Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas. Expert Opinion on Pharmacotherapy, 15, 2087-2103. doi:10.1517/14656566.2014.953928

Belaiche, S., Yafour, N., Balcaen, S., Beguin, Y., Borel, C., Bruno, B., Godin, S., Labussière-Wallet, H., Sanhamut, N., Charbonnier, A., de Berranger, E., Konopacki-Potet, J., Turlure, P., & Yakoub-Agha, I. (2014). Immunosuppresseurs dans la prévention de la réaction du greffon contre l'hôte : rapport de la SFGM-TC. Pathologie Biologie, 62, 197-203. doi:10.1016/j.patbio.2014.05.010

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, (doi:10.1371), 113764. doi:10.1371/journal.pone.0113764

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta - Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001

CAERS, J., & BEGUIN, Y. (2014). Le myélome multiple asymptomatique : le paysage thérapeutique change. Oncol. Hematol, 8, 39-45.

CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46.

Chevallier, P., Labopin, M., Milpied, N., Bilger, K., Socié, G., Yakoub-Agha, I., Michallet, M., Bulabois, C.-E., Maury, S., Beguin, Y., Bay, J.-O., Blaise, D., Maillard, N., Guillerm, G., Daguindeau, E., Raus, N., & Mohty, M. (2014). Outcomes of adults with active or progressive hematological malignancies at time of allogeneic stem cell transplantation : a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplantation, 49, 361-365.

Damaj, G., Mohty, M., Robin, M., Michallet, M., Chevallier, P., Beguin, Y., Nguyen, S., Bories, P., Blaise, D., Maillard, N., Rubio, M.-T., Fegueux, N., Cornillon, J., Clavert, A., Huynh, A., Adès, L., Thiébaut-Bertrand, A., Hermine, O., Vigouroux, S., & Yakoub-Agha, I. (2014). Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome : a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biology of Blood and Marrow Transplantation, 20, 1349-1355. doi:10.1016/j.bbmt.2014.05.010

Delforge, M., Selleslag, D., BEGUIN, Y., Triffet, A., Mineur, P., Theunissen, K., Graux, C., Trullemans, F., Boulet, D., Van Eygen, K., Noens, L., Van Steenweghen, S., Lemmens, J., Pierre, P., D'Hondt, R., Ferrant, A., Deeren, D., Van de Velde, A., Wynendaeke, W., & Ravoet, C. (2014). Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients wih lower risk myelodysplastic syndromes. Leukemia Research, 38, 557-563.

Duléry, R., Mohty, M., Duhamel, A., Robin, M., BEGUIN, Y., Michallet, M., Vigouroux, S., Lioure, B., Garnier, A., El Cheikh, J., Bulabois, C.-E., Huynh, A., Bay, J.-O., Daguindau, E., Ceballos, P., Clément, L., Dauriac, C., Maillard, N., Legrand, F., & Yakoub-Agha, I. (2014). Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome : a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 20, 646-654. doi:10.1016/j.bbmt.2014.01.016

Erpicum, P., DETRY, O., WEEKERS, L., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2014). Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrology Dialysis Transplantation, 29, 1487-1493. doi:10.1093/ndt/gft538

Heusschen, R., Schulkens, I., Muller, J., Griffoen, A., Beguin, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades. International Journal of Molecular Medicine.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (2014). Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation. Belgian Journal of Hematology, 14.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2014). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial. Blood, 124, 33-41. doi:10.1182/blood-2014-01-546333

LECHANTEUR, C., Baila, S., Janssen, M. E., GIET, O., BRIQUET, A., BAUDOUX, E., & Beguin, Y. (2014). Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks. Journal of Stem Cell Research and Therapy, 4 (8), 1000222. doi:10.4172/2157- 7633.1000222

Ludwig, H. P., Aapro, M. S., Bokemeyer, C., Glaspy, J. A., Hedenus, M., Littlewood, T. J., Osterborg, A. C., Rzychon, B., Mitchell, D., & BEGUIN, Y. (2014). A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Supportive Care in Cancer, 22, 2197-2206. doi:10.1007/s00520-014-2189-0

MOERMANS, C., LECHANTEUR, C., BAUDOUX, E., GIET, O., HENKET, M., SEIDEL, L., LEJEUNE, M., WILLEMS, E., Baron, F., LOUIS, R., & BEGUIN, Y. (2014). Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation, 98 (3), 348-353. doi:10.1097/TP.0000000000000068

Moors, I., Schoemans, H., Callens, S., Beguin, Y., & Kerre, T. (2014). Vaccination guidelines in hematopoietic transplant patients : recommendations from the BHS Transplant Committee. Belgian Journal of Hematology, 6, 44-54.

Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology.

SID, S., Dugauquier, D., DE PRIJCK, B., Bonnet, C., & Beguin, Y. (2014). Hemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency. Belgian Journal of Hematology, 17-18.

VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418

Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology.

COLLINS, P., Vijgen, S., DE PRIJCK, B., BLETARD, N., Beguin, Y., & Delvenne, P. (2013). Chimiothérapie, immunodépression et cancers secondaires : rapport d'un cas clinique. Revue Médicale de Liège, 67, 418-422.

De Bock, M., Fillet, M., Hannon, M., Seidel, L., Merville, M.-P., Gothot, A., Beguin, Y., & Baron, F. (2013). Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning. PLoS ONE, 8 (2), 55876. doi:10.1371/journal.pone.0055876

HAFRAOUI, K., DE PRIJCK, B., & Beguin, Y. (2013). Leucémie myélomonocytaire chronique : diagnostic et thérapeutique. Revue Médicale Suisse, 9, 1512-1517.

Janssens, A., Lambert, C., Bries, G., Bosly, A., Selleslag, D., & Beguin, Y. (2013). Primary immune thrombocytopenia in adults. Belgian Journal of Hematology, 4 (1), 2-11.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2013). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. Belgian Journal of Hematology, 16.

Moermans, C., Poulet, C., HENKET, M., Bonnet, C., WILLEMS, E., Baron, F., Beguin, Y., & Louis, R. (2013). Lung function and airway inflammation monitoring after hematopoietic stem cell transplantation. Respiratory Medicine, 107, 2071-2080. doi:10.1016/j.rmed.2013.10.013

Otjacques, E., Binsfeld, M., Beguin, Y., Noël, A., Cataldo, D., & CAERS, J. (2013). Aspects biologiques de l'angiogenèse dans le myélome multiple. Oncohématologie, 7 (2), 6-12.

Otjacques, E., Binsfeld, M., Rocks, N., Blacher, S., Vanderkerken, K., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2013). Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors. PLoS ONE, 8 (5), 62818. doi:10.1371/journal.pone.0062818

Park, S., Labopin, M., Yakoub-Agha, I., Delaunay, J., Dhedin, N., Deconinck, E., Michallet, M., Robin, M., De Revel, T., Bernard, M., Vey, N., Lioure, B., Lapusan, S., Tabrizi, R., Bourhis, J.-H., Huynh, A., Beguin, Y., Socié, G., Dreyfus, F., & Mohty, M. (2013). Allogeneic stem cell transplantation for chronic myelomonocytic leukemia : a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. European Journal of Haematology, 90, 355-364. doi:10.1111/ejh.12073

SERVAIS, S., Beguin, Y., & Baron, F. (2013). Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs, 18 (2), 173-192. doi:10.1517/14728214.2013.798642

SERVAIS, S., WILLEMS, E., Beguin, Y., & Baron, F. (2013). Allogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ? Revue Médicale de Liège, 68 (1), 38-43.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (February 2012). Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft. Biology of Blood and Marrow Transplantation, 18 (2), 274-S275. doi:10.1016/j.bbmt.2011.12.193

Aapro, M. S., Osterborg, A. C., Gascon, P., Ludwig, H. P., & BEGUIN, Y. (2012). Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Annals of Oncology, 23, 1954-62.

Aapro, M. S., Österborg, A., Gascon, P., Ludwig, H., & Beguin, Y. (2012). Anaemia and cancer : oral or intravenous iron ? Therapeutics, 46-48.

Belle, L., Bruck, F., FOGUENNE, J., GOTHOT, A., BEGUIN, Y., Baron, F., & Briquet, A. (2012). Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34+ Cells. PLoS ONE, 7 (12), 52564. doi:10.1371/journal.pone.0052564

Binsfeld, M., Belle, L., Hannon, M., Hofgaard, Dubois, S., Otjacques, E., BEGUIN, Y., Bogen, BARON, F., & CAERS, J. (2012). Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation. Bone Marrow Transplantation, 47 (Suppl.1).

Bonnet, C., DE PRIJCK, B., LEJEUNE, M., FASSOTTE, M.-F., Van Den Neste, E., & Beguin, Y. (2012). Prise en charge du lymphome B diffus à grandes cellules en 2012. Revue Médicale Suisse, 8, 1582-90.

Damaj, G., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., Mohty, M., Vigouroux, S., Bories, P., Garnier, A., El Cheikh, J., Bulabois, C.-E., Huynh, A., Bay, J.-O., Legrand, F., Deconinck, E., Fegueux, N., Clement, L., Dauriac, C., Maillard, N., & Yakoub-Agha, I. (2012). Impact of Azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes : a study b the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe Francophone des Myélodysplasies. Journal of Clinical Oncology, 30, 4533-4540. doi:10.1200/JCO.2012.44.3499

FRUSCH, N., SERVAIS, S., DE PRIJCK, B., Corhay, J.-L., Beguin, Y., Louis, R., & DUYSINX, B. (2012). Spontaneous pneumomediastinum caused by bleomycin-induced pneumonitis. Acta Clinica Belgica, 67-68. doi:10.2143/ACB.67.5.2062693

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2012). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Haematologica, 97 (Supplement 1), 180.

Huybrechts, S., BEGUIN, Y., Bordon, V., DRESSE, M.-F., Dupont, S., Ferster, A., Laureys, G., Meyts, I., Renard, M., & Vermylen, C. (2012). Less veno-occlusive disease after intravenous versus oral busulfan for autologous haematopoietic stem cell transp.l antation: the Belgian paediatric experlence. Belgian Journal of Hematology, 3 (2), 34-40.

Malaise, O., FRUSCH, N., BECK, E., Servais, S., BETEA, D., CAERS, J., DE PRIJCK, B., & BEGUIN, Y. (2012). Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma. Leukemia and Lymphoma, 53 (12), 2515-16.

MENTEN, C., Castermans, E., Hannon, M., Ormenese, S., Beguin, Y., & Baron, F. (2012). What is the Contribution of Host-Derived CMV Immunity after Allogeneic Transplantation following Non-Myeloablative Conditioning? Haematologica, 97 (Supplement 1), 720.

Roelants, V., DELGAUDINE, M., Walrand, S., Lhommel, R., Beguin, Y., Jamar, F., & Vanoverschelde, J.-L. (2012). Myocardial infarct size quantification in mice by SPECT using a novel algorithm independent of a normal perfusion database. EJNMMI Research, 2, 64-75. doi:10.1186/2191-219X-2-64

VANDAMME, A., Schots, R., & BEGUIN, Y. (2012). Academic clinical trials run by the transplant committee of the Belgian Hematological Society. Belgian Journal of Hematology, 3 (2), 62-67.

Verbeke, N., Beguin, Y., Wildiers, H., Canon, J.-L., Bries, G., Bosly, A., & Van Belle, S. (2012). High prevalence of anaemia and limited use of therapy in cancer patients : a Belgian survey (Anaemia Day 2008). Supportive Care in Cancer, 20, 23-28. doi:10.1007/s00520-010-1045-0

VERTENOEIL, G., SERVAIS, S., & Beguin, Y. (2012). Comment j'explore... une fièvre d'origine indéterminée chez le patient adulte ? Revue Médicale de Liège, 67 (7-8), 391-397.

Zeddou, M., RELIC, B., MALAISE, O., CHARLIER, E., Desouroux, A., BEGUIN, Y., DE SENY, D., & Malaise, M. (2012). Differential signalling through ALK-1 and ALK-5 regulates leptin expression in Mesenchymal Stem Cells. Stem Cells and Development, 21 (11), 1948-54. doi:10.1089/scd.2011.0321

Noterdaeme, T., Longree, L., Bataille, C., DE ROOVER, A., LAMPROYE, A., DELWAIDE, J., Beguin, Y., Honoré, P., & DETRY, O. (July 2011). Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients. World Journal of Gastroenterology, 17 (25), 3069-72. doi:10.3748/wjg.v17.i25.3069

Aapro, M. S., Beguin, Y., Birgegard, G., Gascon, P., Hedenus, M., & Osterborg, A. (2011). Too low iron doses and too many dropouts in negative iron trial. Journal of Clinical Oncology, 525-e526. doi:10.1200/JCO.2011.35.3219

Bonnet, C., CAERS, J., DE PRIJCK, B., HAFRAOUI, K., & Beguin, Y. (2011). Lymphome du manteau : prise en charge 2011. Revue Médicale Suisse, 7, 1644-1649.

CAERS, J., BONNET, C., GRAUX, C., DE PRIJCK, B., & BEGUIN, Y. (2011). Prise en charge actuelle des syndromes myélodysplasiques. Revue Médicale Suisse, 7, 1634-1643.

CASTERMANS, E., Hannon, M., Dutrieux, J., Humblet, S., Seidel, L., Cheynier, R., Willems, E., Gothot, A., Vanbellinghen, J.-F., Geenen, V., Sandmaier, B. M., Storb, R., Beguin, Y., & Baron, F. (2011). Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of age. Haematologica, 96(2), 298-306. doi:10.3324/haematol.2010.029702

DELGAUDINE, M., Lambermont, B., Lancellotti, P., Roelants, V., Walrand, S., Vanoverschelde, J.-L., Pierard, L., Gothot, A., & Beguin, Y. (2011). Effects of granulocyte-colony-stimulating factor on progenitor cell mobilization and heart perfusion and function in normal mice. Cytotherapy, 13, 237-247. doi:10.3109/14653249.2010.491820

Robin, M., Sanz, G. F., Ionescu, I., Rio, B., Sirvent, A., Renaud, M., Carreras, E., Milpied, N., Mohty, M., Beguin, Y., Bordigoni, P., De Witte, T., Picardi, A., Purtill, D., Gluckman, E., Kroger, N., & Rocha, V. (2011). Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia : a survey on behalf of Eurocord and CLWP of EBMT. Leukemia, 25, 75-81. doi:10.1038/leu.2010.219

SERVAIS, S., Baron, F., & Beguin, Y. (2011). Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfusion and Apheresis Science, 44, 205-210. doi:10.1016/j.transci.2011.01.019

Servais, S., Beguin, Y., & Baron, F. (2011). Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). Belgian Journal of Hematology, 2, 3-9.

Baron, F., & Beguin, Y. (2010). Hematopoietic stem cell transplantation in the treatment strategy of acute leukemia. Belgian Journal of Medical Oncology, 4, 118-123.

Briquet, A., Dubois, S., Bekaert, S., Dolhet, M., Beguin, Y., & Gothot, A. (2010). Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID -repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95 (1), 47-56. doi:10.3324/haematol.2009.008524

Dirix, L., Awada, A., Bron, D., Canon, J.-L., De Grève, J., Humblet, Y., Peeters, M., Van Belle, S., Vansteenkiste, J., Beguin, Y., & Vermorken, J. (2010). Practice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia. Belgian Journal of Medical Oncology, 4, 57-64.

Jaspers, A., Baron, F., Bonnet, C., De Prijck, B., Fassotte, M.-F., & Beguin, Y. (2010). Le lymphome du manteau. Revue Médicale de Liège, 65, 171-176.

Roufosse, R., & Beguin, Y. (2010). Observance thérapeutique en hématologie : le cas particulier de la leucémie myéloïde chronique. Revue Médicale de Liège, 65, 409-412.

Servais, S., Caers, J., Warling, O., Frusch, N., Baron, F., De Prijck, B., & Beguin, Y. (2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. British Journal of Haematology, 150 (3), 379-381. doi:10.1111/j.1365-2141.2010.08202.x

Servais, S., Willems, E., Beguin, Y., & Baron, F. (2010). Maladie du greffon contre l'hôte chronique : une prise en charge multidisciplinaire. Revue Médicale de Liège, 65, 81-87.

Willems, E.* , Baron, F.* , Seidel, L., Frère, P., Fillet, G., & Beguin, Y. (2010). Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 689-693. doi:10.1038/bmt.2009.230

Willems, E., Humblet-Baron, S., Dengis, O., Seidel, L., Beguin, Y., & Baron, F. (2010). Elevations of tumor necrosis factor-receptor-1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 1442-1448. doi:10.1038/bmt.2009.360

Humblet-Baron, S., CASTERMANS, E., Vanbellinghen, J.-F., Hannon, M., Jacobs, N., WILLEMS, E., Ormenese, S., Beguin, Y., & Baron, F. (February 2009). What Is The Role For Regulatory T-Cells After Nonmyeloablative Conditioning? Biology of Blood and Marrow Transplantation, 15 (2), 122-123. doi:10.1016/j.bbmt.2008.12.377

Avivi, I., Montoto, S., Canals, C., Maertens, J., Al-Ali, H., Mufti, G. J., Finke, J., Schattenberg, A., Fanin, R., Cornelissen, J. J., Vernant, J.-P., Russel, N., Beguin, Y., Thomason, K., Verdonck, L. F., Kobbe, G., Tilly, H., Socié, G., & Sureda, A. (2009). Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma : an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 147, 719-728. doi:10.1111/j.1365-2141.2009.07905.x

Beguin, Y. (2009). Utilisation thérapeutique de l'érythropoïétine. Revue du Praticien, 59, 82-83.

Bonnet, C., Beguin, Y., De Prijck, B., de Leval, L., & Fillet, G. (2009). Traitements actuels du lymphome folliculaire. Revue Médicale Suisse, 5, 1663-7.

Bonnet, C., Beguin, Y., De Prijck, B., Witvrouw, N., Hustinx, R., & Fillet, G. (2009). Les anticorps monoclonaux en hématologie en 2009. Revue Médicale de Liège, 64, 268-273.

Briquet, A., Dolhet, M., Beguin, Y., & Gothot, A. (2009). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells. Experimental Hematology, 37 (9), 77.

Castermans, E., Hannon, M., Cheynier, R., Seidel, L., Humblet-Baron, S., WILLEMS, E., Corbier, S., Gothot, A., Geenen, V., Sandmaier, B. M., Storb, R. F., Beguin, Y., & Baron, F. (2009). Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age. Blood, 114 (22), 1149.

Castermans, E., Hannon, M., Drion, P., Geenen, V., Beguin, Y., & Baron, F. (2009). Reconstitution du système immunitaire après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (S1), 2-8.

Dugauquier, C., Bataille, Y., Willems, E., Frere, P., De Prijck, B., Beguin, Y., & Baron, F. (2009). Toxoplasmore cérébrale compliquant une mini-allogreffe de cellules souches hématopoïétiques du sang périphérique. Revue Médicale de Liège, 64 (7-8), 366-369.

Hafraoui, K., Beguin, Y., & Baron, F. (2009). Cancers secondaires après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (10), 496-499.

Morrhaye, G., Kermani, H., Legros, J.-J., Baron, F., Beguin, Y., Moutschen, M., Cheynier, R., Martens, H., & Geenen, V. (2009). Impact of growth hormone (GH) deficiency and GH replacement upon thymus function in adult patients. PLoS ONE, 4 (5), 5668. doi:10.1371/journal.pone.0005668

Relic, B., Zeddou, M., Desoroux, A., Beguin, Y., De Seny, D., & Malaise, M. (2009). Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts. Laboratory Investigation, 89 (7), 811-822. doi:10.1038/labinvest.2009.41

Willems, E.* , Baron, F.* , Baudoux, E., Wanten, N., Seidel, L., Vanbellinghen, J.-F., Herens, C., Gothot, A., Frere, P., Bonnet, C., Hafraoui, K., Vanstraelen, G., Fillet, G., & Beguin, Y. (2009). Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia, 23 (3), 608-10. doi:10.1038/leu.2008.248

Willems, E., Canivet, J.-L., Ghaye, B., de Leval, L., Radermecker, M., Preiser, J.-C., & Beguin, Y. (2009). Pulmonary veno-occlusive disease in myeloproliferative disorder. European Respiratory Journal, 33 (1), 213-216. doi:10.1183/09031936.00157707

Willemze, R., Rodrigues, C. A., Labopin, M., Sanz, G., Michel, G., Socié, G., Rio, B., Sirvent, A., Renaud, M., Madero, L., Mothy, M., Ribera, J. M., Garnier, F., Garcia, J., Lecchi, L., Kögler, G., Beguin, Y., Navarette, C., Boogaerts, M., & Rocha, V. (2009). KIR-ligand incompatibility in the Graft-versus-host direction improves outcome after umbilical cord blood transplantation for acute leukemia. Leukemia, 23, 492-500. doi:10.1038/leu.2008.365

Humblet-Baron, S., CASTERMANS, E., Vanbellighen, J.-F., Hannon, M., Jacobs, N., Beguin, Y., & Baron, F. (February 2008). What is the Role for Regulatory T-Cells after Nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 14 (2), 136-137. doi:10.1016/j.bbmt.2007.12.383

Beguin, Y. (2008). Le sang de cordon ombilical. Revue du Praticien, 58, 2107-08.

Brand, A., Rebulla, P., Engelfriet, C. P., Reesink, H. W., Beguin, Y., Baudoux, E., Kögler, G., Ebrahimi, M., Grazzini, G., Costa, A. N., Bosi, A., Sacchi, S., Lombardini, L., Pupella, S., Lecchi, L., Calderon Garciduenas, E. D., van Beckhoven, J. M., de Wit, H. J. C., Fibbe, W. E., & Regan, F. (2008). Cord blood banking. Vox Sanguinis, 95, 335-348. doi:10.1111/j.1423-0410.2008.01106.x

Castermans, E.* , Baron, F.* , Willems, E., Schaaf-Lafontaine, N., Meuris, N., Gothot, A., Vanbellinghen, J.-F., Herens, C., Seidel, L., Geenen, V., Cheynier, R., & Beguin, Y. (2008). Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica, 93 (2), 240-7. doi:10.3324/haematol.11708

Hoyoux, C., Dresse, M.-F., Robinet, S., Forget, P., Pieltain, C., Ketelslegers, O., & Beguin, Y. (2008). Cord blood transplantation in a child with Pearson's disease. Pediatric Blood and Cancer, 51 (4), 566. doi:10.1002/pbc.21615

Lejeune, M., Beguin, Y., De Prijck, B., Fassotte, M.-F., Fillet, G., & Baron, F. (2008). Comment je traite...La leucémie myéloblastique aiguë (LMA) du sujet age en bon état général. Revue Médicale de Liège, 63 (2), 59-63.

Briquet, A., Dolhet, M., Demeuse, J., BEGUIN, Y., & GOTHOT, A. (August 2007). Study of contribution of signalling pathways Notch, Wnt, Shh and BMP in mesenchymal stem cell prohaematopoietic activity. Acta Clinica Belgica, 62 (4), 256.

Bovy, C., Gothot, A., Krzesinski, J.-M., Warling, X., & Beguin, Y. (20 January 2007). Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrology Dialysis Transplantation, 11, 1156-1162. doi:10.1093/ndt/gfl765

Bonnet, C., Beguin, Y., Fassotte, M.-F., Seidel, L., Luyckx, F., & Fillet, G. (2007). Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. European Journal of Haematology, 78 (5), 399-404. doi:10.1111/j.1600-0609.2007.00843.x

Castermans, E., Morrhaye, G., Marchand, S., Martens, H., Moutschen, M., Baron, F., Beguin, Y., & Geenen, V. (2007). Evaluation clinique de la fonction du thymus. Revue Médicale de Liège, 62 (11), 675-8.

Castermans, E., Morrhaye, G., Marchand, S., Martens, H., Moutschen, M., Geenen, V., Beguin, Y., & Baron, F. (2007). Evaluation de la thymopoiese: applications cliniques. Revue Médicale de Liège, 62 (12), 725-9.

De Prijck, B., Baron, F., Beguin, Y., Bonnet, C., Willems, E., & Fillet, G. (2007). Actualités thérapeutiques en hématologie. Revue Médicale de Liège, 62 (5-6), 384-90.

Baron, F., Vanstraelen, G., & Beguin, Y. (2006). Transfusions after nonmyeloablative or reduced-intensity conditioning regimens. Leukemia, 20 (12), 2081-6. doi:10.1038/sj.leu.2404431

Bovy, C., Baudoux, E., Salmon, J., & Beguin, Y. (2006). Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy. Transfusion, 46 (9), 1616-23. doi:10.1111/j.1537-2995.2006.00945.x

Cavill, I., Auerbach, M., Bailie, G. R., Barrett-Lee, P., Beguin, Y., Kaltwasser, P., Littlewood, T., Macdougall, I. C., & Wilson, K. (2006). Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion, 22 (4), 731-7. doi:10.1185/030079906X100096

Frere, P., Baron, F., Bonnet, C., Hafraoui, K., Pereira-Martins, M., Willems, E., Fillet, G., & Beguin, Y. (2006). Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplantation, 37 (4), 411-8. doi:10.1038/sj.bmt.1705255

Frere, P., Pereira-Martins, M., Fillet, G., & Beguin, Y. (2006). Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. European Journal of Haematology, 76 (2), 102-8. doi:10.1111/j.1600-0609.2005.00569.x

Pirson, L.* , Baron, F.* , Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2006). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells, 24 (7), 1814-21. doi:10.1634/stemcells.2005-0290

Van Overstraeten-Schlogel, N., Beguin, Y., & Gothot, A. (2006). Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. European Journal of Haematology, 76 (6), 488-93. doi:10.1111/j.1600-0609.2006.00633.x

Van Overstraeten-Schlogel, N., Delgaudine, M., Beguin, Y., & Gothot, A. (2006). Limitations of the use of GFP transgenic mice in bone marrow transplantation studies. Leukemia and Lymphoma, 47 (7), 1392-3. doi:10.1080/10428190500513512

Vanstraelen, G., Baron, F., Willems, E., Bonnet, C., Hafraoui, K., Frere, P., Fillet, G., & Beguin, Y. (2006). Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response. Experimental Hematology, 34 (7), 841-50. doi:10.1016/j.exphem.2006.04.012

Vanstraelen, G., Frere, P., Ngirabacu, M.-C., Willems, E., Fillet, G., & Beguin, Y. (2006). Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Experimental Hematology, 34 (3), 382-8. doi:10.1016/j.exphem.2005.11.013

Bataille, Y., Bovy, C., Lancellotti, P., Melchior, V., Delbecque, K., Beguin, Y., & Krzesinski, J.-M. (2005). Primary amyloidosis (AL) as a cause of nephrotic syndrome. Acta Clinica Belgica, 60 (2), 94-7. doi:10.1179/acb.2005.017

Beguin, Y. (2005). Intravenous iron and recombinant human erythropoietin in cancer patients. Journal of Clinical Oncology, 23 (3), 651-2; author reply 652-3. doi:10.1200/JCO.2005.05.184

Bovy, C., Gothot, A., Krzesinski, J.-M., & Beguin, Y. (2005). Mature erythrocyte indices: new markers of iron availability. Haematologica, 90 (4), 549-51.

Foguenne, J., Huygen, S., Greimers, R., Beguin, Y., & Gothot, A. (2005). Modulation of homing properties of primitive progenitor cells generated by ex vivo expansion. Haematologica, 90 (4), 445-51.

Glaspy, J., & Beguin, Y. (2005). Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology, 69 Suppl 2, 8-16. doi:10.1159/000088283

Piette, C., Dresse, M.-F., Forget, P., Schmitz, V., Demarche, M., Erpicum, P., Closon, M.-T., Rutten, I., Paulus, P., Vivegnis, D., Beguin, Y., Jamblin, P., & Hoyoux, C. (2005). Les neuroblastomes de l'enfant. A propos de 23 cas. Revue Médicale de Liège, 60 (3), 173-80.

T'Sjoen, G., Beguin, Y., Feyen, E., Rubens, R., Kaufman, J.-M., & Gooren, L. (2005). Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma. Journal of Endocrinology, 186 (1), 61-7. doi:10.1677/joe.1.06112

Vanstraelen, G., Baron, F., Frere, P., Hafraoui, K., Fillet, G., & Beguin, Y. (2005). Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica, 90 (9), 1269-70.

Willems, E., Baron, F., Vanstraelen, G., Frere, P., Fillet, G., & Beguin, Y. (2005). Immunotherapie du cancer par minigreffe de cellules souches hematopoietiques. Revue Médicale Suisse, 1 (30), 1973-7.

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2005). Nonmyeloablative stem cell transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a prospective randomized trial. Blood, 106 (1075).

Beguin, Y., & Weber, G. (2004). Serum selenium in lymphoma. Journal of Clinical Oncology, 22 (16), 3429; author reply 3430. doi:10.1200/JCO.2004.99.240

Bovy, C., Krzesinski, J.-M., Gothot, A., & Beguin, Y. (2004). Impact of erythropoietic activity on red cell parameters in chronic renal failure patients. Haematologica, 89 (6), 748-9.

Frere, P., Hermanne, J.-P., Debouge, M.-H., De Mol, P., Fillet, G., & Beguin, Y. (2004). Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplantation, 33 (7), 745-9. doi:10.1038/sj.bmt.1704414

Passweg, J. R., Rabusin, M., Musso, M., Beguin, Y., Cesaro, S., Ehninger, G., Espigado, I., Iriondo, A., Jost, L., Koza, V., Lenhoff, S., Lisukov, I., Locatelli, F., Marmont, A., Philippe, Pilatrino, C., Quartier, P., Stary, J., Veys, P., & Gratwohl, A. (2004). Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. British Journal of Haematology, 125 (6), 749-55. doi:10.1111/j.1365-2141.2004.04978.x

Baron, F., Baudoux, E., Frere, P., Tourqui, S., Schaaf-Lafontaine, N., Herens, C., De Prijck, B., Fillet, G., & Beguin, Y. (2003). Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC. Bone Marrow Transplantation, 32 (8), 829-34. doi:10.1038/sj.bmt.1704220

Baron, F., DRESSE, M.-F., & Beguin, Y. (2003). Transmission of chronic myeloid leukemia through peripheral-blood stem-cell transplantation. New England Journal of Medicine, 349 (9), 913-4. doi:10.1056/NEJM200308283490921

Baron, F., Frere, P., Baudoux, E., Sautois, B., Fillet, G., & Beguin, Y. (2003). Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica, 88 (4), 478-80.

Baron, F., Frere, P., Baudoux, E., Schaaf-Lafontaine, N., Fillet, G., & Beguin, Y. (2003). Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. Haematologica, 88 (7), 835-7.

Baron, F., Frere, P., & Beguin, Y. (2003). Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica, 88 (6), 718-20.

Baron, F., Frere, P., Fillet, G., & Beguin, Y. (2003). Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. British Journal of Haematology, 123 (1), 103-5. doi:10.1046/j.1365-2141.2003.04556.x

Baron, F., Frere, P., Fillet, G., & Beguin, Y. (2003). Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clinical Cancer Research, 9 (15), 5566-72.

Baron, F., Schaaf-Lafontaine, N., Humblet-Baron, S., Meuris, N., Castermans, E., Baudoux, E., Frere, P., Bours, V., Fillet, G., & Beguin, Y. (2003). T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation, 76 (12), 1705-13. doi:10.1097/01.TP.0000093987.11389.F7

Beguin, Y. (2003). Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clinica Chimica Acta, 329 (1-2), 9-22. doi:10.1016/S0009-8981(03)00005-6

Beguin, Y., & Baron, F. (2003). Minitransplants: allogeneic stem cell transplantation with reduced toxicity. Acta Clinica Belgica, 58 (1), 37-45. doi:10.1179/acb.2003.58.1.005

Bovy, C., Beguin, Y., Gothot, A., Rorive, G., & Krzesinski, J.-M. (2003). Hypochromic mature erythrocytes: a specific marker of iron deficiency. Acta Clinica Belgica, 58-3 (4), 325.

Bovy, C., Beguin, Y., Gothot, A., Rorive, G., & Krzesinski, J.-M. (2003). Follow-up of iron microalbuminuria in hypertensive patients: a belgian promise survey. Acta Clinica Belgica, 58-3 (4), 328.

Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I., & Coiffier, B. (2003). Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 122 (3), 386-93. doi:10.1046/j.1365-2141.2003.04439.x

Gothot, A., Giet, O., Huygen, S., & Beguin, Y. (2003). Binding and migration across fibronectin and VCAM-1 of cycling hematopoietic progenitor cells. Leukemia and Lymphoma, 44 (8), 1379-83. doi:10.1080/1042819031000083406

Hafraoui, K., Humblet-Baron, S., Baron, F., Beguin, Y., & Fillet, G. (2003). Comment je traite ... la leucemie myeloide chronique (LMC). Revue Médicale de Liège, 58 (1), 7-12.

Humblet-Baron, S., Baron, F., Chachati, A., Bury, J., Morelon, E., Kreis, H., & BEGUIN, Y. (2003). Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia. Transplantation, 76 (10), 1531-2. doi:10.1097/01.TP.0000085285.59061.D7

Schetelig, J., Fetscher, S., Reichle, A., Berdel, W. E., Beguin, Y., Brunet, S., Caballero, D., Majolino, I., Hagberg, H., Johnsen, H. E., Kimby, E., Montserrat, E., Stewart, D., Copplestone, A., Rosler, W., Pavel, J., Kingreen, D., & Siegert, W. (2003). Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica, 88 (11), 1272-8.

Baron, F., Baudoux, E., Fillet, G., & Beguin, Y. (2002). Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipulated bone marrow transplantation. Hematology, 7 (3), 137-43. doi:10.1080/1024533021000008173

Baron, F., Baudoux, E., Frere, P., Tourqui, S., Schaaf-Lafontaine, N., Greimers, R., Herens, C., Fillet, G., & Beguin, Y. (2002). Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. Journal of Hematotherapy and Stem Cell Research, 11 (2), 301-14. doi:10.1089/152581602753658484

Baron, F., & Beguin, Y. (2002). Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 8 (7), 351-9. doi:10.1053/bbmt.2002.v8.pm12171481

Baron, F., & Beguin, Y. (2002). Nonmyeloablative allogeneic hematopoietic stem cell transplantation. Journal of Hematotherapy and Stem Cell Research, 11 (2), 243-63. doi:10.1089/152581602753658448

Baron, F., Fillet, G., & Beguin, Y. (2002). Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation, 74 (12), 1692-6. doi:10.1097/00007890-200212270-00008

Baron, F., Frere, P., Herens, C., Fillet, G., & Beguin, Y. (2002). Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML. Haematologica, 87 (12), 43.

Baron, F., Sautois, B., Baudoux, E., Matus, G., Fillet, G., & Beguin, Y. (2002). Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 30 (6), 546-54. doi:10.1016/S0301-472X(02)00795-6

Baron, F., Siquet, J., Schaaf-Lafontaine, N., Baudoux, E., Hermanne, J.-P., Fillet, G., & Beguin, Y. (2002). Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica, 87 (1), 78-88.

Beguin, Y. (2002). Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica, 87 (11), 1209-21.

Beguin, Y. (2002). Le métabolisme du fer. Hématologie, 8, 7-S11.

Beguin, Y., Benoit, Y., Crokaert, F., Selleslag, D., & Vandercam, B. (2002). Outpatient and home parenteral antibiotic therapy (OHPAT) in low-risk febrile neutropenia: consensus statement of a Belgian panel. Acta Clinica Belgica, 57 (6), 309-16. doi:10.1179/acb.2002.058

Engelfriet, C. P., Reesink, H. W., Wagner, J. E., Kogler, G., Rocha, V., Wernet, P., Lecchi, L., Lazzari, L., Ratti, I., Giovanelli, S., Poli, F., Rebulla, P., Beguin, Y., Baudoux, E., Navarrete, C., Armitage, S., Laughlin, M. J., & McClelland, W. M. (2002). International forum. Use of umbilical cord blood progenitor cells as an alternative for bone marrow transplantation. Vox Sanguinis, 83 (2), 172-87. doi:10.1046/j.1423-0410.2002.00197.x

Frere, P., Hermanne, J.-P., Debouge, M.-H., Fillet, G., & Beguin, Y. (2002). Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 29 (7), 589-94. doi:10.1038/sj/bmt/1703413

Giet, O., Van Bockstaele, D. R., Di Stefano, I., Huygen, S., Greimers, R., Beguin, Y., & Gothot, A. (2002). Increased binding and defective migration across fibronectin of cycling hematopoietic progenitor cells. Blood, 99 (6), 2023-31. doi:10.1182/blood.V99.6.2023

Gothot, A., Giet, O., Huygen, S., & Beguin, Y. (2002). Modulation par le cycle cellulaire de l'implantation des cellules souches hématopoïétiques. Hématologie, 8, 397-404.

Huygen, S., Giet, O., Artisien, V., Di Stefano, I., Beguin, Y., & Gothot, A. (2002). Adhesion of synchronized human hematopoietic progenitor cells to fibronectin and vascular cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo culture. Blood, 100 (8), 2744-52. doi:10.1182/blood.V100.8.2744

Verhoef, H., West, C. E., Veenemans, J., Beguin, Y., & Kok, F. J. (2002). Stunting may determine the severity of malaria-associated anemia in African children. Pediatrics, 110 (4), 48. doi:10.1542/peds.110.4.e48

Warland, V., Jerusalem, G., Hustinx, R., Beguin, Y., Silvestre, R. M., Fassotte, M.-F., Foidart, J., & Fillet, G. (2002). Comment etablir le bilan de fin de traitement des patients atteints de lymphomes non-hodgkiniens (LNH) de malignite intermediaire ou elevee? Revue Médicale de Liège, 57 (12), 779-84.

Baron, F., Frere, P., Fillet, G., & Beguin, Y. (2001). Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica, 86 (9), 993-4.

Beguin, Y. (2001). Intérêt du dosage du récepteur soluble de la transferrine (sTfR) pour l'évaluation de l'érythropoïèse et de l'état du fer. Hématologie, 7, 161-169.

Fillet, G., & Beguin, Y. (2001). Monitoring of erythropoiesis by the serum transferrin receptor and erythropoietin. Acta Clinica Belgica, 56 (3), 146-54. doi:10.1179/acb.2001.024

Giet, O., Huygen, S., Beguin, Y., & Gothot, A. (2001). Cell cycle activation of hematopoietic progenitor cells increases very late antigen-5-mediated adhesion to fibronectin. Experimental Hematology, 29 (4), 515-24. doi:10.1016/S0301-472X(00)00682-2

Piron, M., Loo, M., Gothot, A., Tassin, F., Fillet, G., & Beguin, Y. (2001). Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood, 97 (2), 442-8. doi:10.1182/blood.V97.2.442

R'Zik, S., & Beguin, Y. (2001). Serum soluble transferrin receptor concentration is an accurate estimate of the mass of tissue receptors. Experimental Hematology, 29 (6), 677-85. doi:10.1016/S0301-472X(01)00641-5

R'Zik, S., Loo, M., & Beguin, Y. (2001). Reticulocyte transferrin receptor (TfR) expression and contribution to soluble TfR levels. Haematologica, 86 (3), 244-51.

Sautois, B., Baudoux, E., Salmon, J., Michaux, S., Schaaf-Lafontaine, N., Pereira-Martins, M., Paulus, J.-M., Fillet, G., & Beguin, Y. (2001). Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation. Haematologica, 86 (11), 1209-18.

Sylvestre, R.-M., Jerusalem, G., Sautois, B., Beguin, Y., & Fillet, G. (2001). Nouvelles approches thérapeutiques puor l'hypernéphrome métastasique. Médecine et Hygiène, 59, 1607-1609.

JERUSALEM, G., & BEGUIN, Y. (June 2000). Commentary on "Positron emission tomography in lymphoma : comparison with computed tomography and Gallium-67 single photon emission computed tomography imaging". Clinical Lymphoma, 1 (1), 75-76.

Baron, F., & Beguin, Y. (2000). Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion, 40 (4), 468-76. doi:10.1046/j.1537-2995.2000.40040468.x

Baron, F., Dresse, M.-F., & Beguin, Y. (2000). Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion, 40 (9), 1071-3. doi:10.1046/j.1537-2995.2000.40091071.x

Baron, F., Gothot, A., Salmon, J., Hermanne, J. P., Pierard, G., Fillet, G., & Beguin, Y. (2000). Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. British Journal of Haematology, 111 (3), 745-53. doi:10.1046/j.1365-2141.2000.02470.x

Frere, P., Canivet, J.-L., Gennigens, C., Rebeix, J. P., Fillet, G., & Beguin, Y. (2000). Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplantation, 26 (3), 343-5. doi:10.1038/sj.bmt.1702485

Herens, C., Tassin, F., Lemaire, V., Beguin, Y., Collard, E., Lampertz, S., Croisiau, C., Desouter-Lecomte, M., DE PRIJCK, B., Longree, L., & Koulischer, L. (2000). Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. British Journal of Haematology, 110 (1), 214-6. doi:10.1046/j.1365-2141.2000.02142.x

Magee, L. A., von Dadelszen, P., Darley, J., & Beguin, Y. (2000). Erythropoiesis and renal transplant pregnancy. Clinical Transplantation, 14 (2), 127-35. doi:10.1034/j.1399-0012.2000.140205.x

Roodenburg, A. J., West, C. E., Beguin, Y., Van Dijk, J. E., Van Eijk, H. G., Marx, J. J., & Beynen, A. C. (2000). Indicators of erythrocyte formation and degradation in rats with either vitamin A or iron deficiency. Journal of Nutritional Biochemistry, 11 (4), 223-30. doi:10.1016/S0955-2863(00)00070-X

Sautois, B., Scerbo, F., Beguin, Y., & Fillet, G. (2000). Traitement des myélomes réfractaires par la Thalidomide. Médecine et Hygiène, 58, 1633-1634.

Beguin, Y. (1999). Erythropoietin and platelet production. Haematologica, 84 (6), 541-7.

Cazzola, M., Beguin, Y., Bergamaschi, G., Guarnone, R., Cerani, P., Barella, S., Cao, A., & Galanello, R. (1999). Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. British Journal of Haematology, 106 (3), 752-5. doi:10.1046/j.1365-2141.1999.01600.x

Dresse, M.-F., Boogaerts, M., Vermylen, C., Noens, L., Ferrant, A., Schots, R., Doyen, C., Bron, D., Berneman, Z., Ferster, A., Benoit, Y., Demuynck, H., & Beguin, Y. (1999). The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor. Haematologica, 84 (7), 637-42.

Loo, M., & Beguin, Y. (1999). The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood, 93 (10), 3286-93. doi:10.1182/blood.v93.10.3286.410k29_3286_3293

Salmon, J., Michaux, S., Hermanne, J. P., Baudoux, E., Gerard, C., Sondag, D., Fillet, G., & Beguin, Y. (1999). Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Transfusion, 39 (8), 824-7. doi:10.1046/j.1537-2995.1999.39080824.x

Baron, F., Hermanne, J.-P., Dowlati, A., Weber, T., Thiry, A., Fassotte, M.-F., Fillet, G., & Beguin, Y. (1998). Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 21 (9), 951-4. doi:10.1038/sj.bmt.1701198

Baron, F., Sadzot, B., Wang, F.-C., & Beguin, Y. (1998). Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 22 (2), 197-200. doi:10.1038/sj.bmt.1701297

Beguin, Y. (1998). Prediction of response to optimize outcome of treatment with erythropoietin. Seminars in Oncology, 25 (3 Suppl 7), 27-34.

Beguin, Y., Baron, F., & Fillet, G. (1998). Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica, 83 (12), 1076-81.

Cazzola, M., Guarnone, R., Cerani, P., Centenara, E., Rovati, A., & Beguin, Y. (1998). Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood, 91 (6), 2139-45. doi:10.1182/blood.v91.6.2139.2139_2139_2145

Corazza, F., Beguin, Y., Bergmann, P., Andre, M.-E., Ferster, A., Devalck, C., Fondu, P., Buyse, M., & Sariban, E. (1998). Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood, 92 (5), 1793-8. doi:10.1182/blood.v92.5.1793.417k23_1793_1798

Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J. M., Winqvist, I., Oberg, G., Osterborg, A., & Ost, A. (1998). Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92 (1), 68-75. doi:10.1182/blood.v92.1.68.413k23_68_75

Pierard, G., Nikkels, N., Nikkels, A., Arrese Estrada, J., Pierard, C., Jerusalem, G., Beguin, Y., & Fillet, G. (1998). Epidermal Calprotectin Expression in Lymphocyte-Depleted Cutaneous Graft-versus-Host Reaction. Archivos Argentinos de Dermatologia, 48, 139-142.

van Iperen, C. E., Kraaijenhagen, R. J., Biesma, D. H., Beguin, Y., Marx, J. J., & van de Wiel, A. (1998). Iron metabolism and erythropoiesis after surgery. British Journal of Surgery, 85 (1), 41-5. doi:10.1046/j.1365-2168.1998.00571.x

Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., Beguin, Y., Dresse, M.-F., & Sariban, E. (1998). Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplantation, 22 (1), 1-6. doi:10.1038/sj.bmt.1701291

Baron, F., Deprez, M., & Beguin, Y. (1997). The veno-occlusive disease of the liver. Haematologica, 82 (6), 718-25.

Beguin, Y., Sautois, B., Forget, P., Bury, J., & Fillet, G. (1997). Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen. Cancer, 79 (7), 1351-4. doi:10.1002/(SICI)1097-0142(19970401)79:7<1351::AID-CNCR12>3.0.CO;2-Z

Cavill, I., Macdougall, I. C., Gokal, R., Beguin, Y., Peters, T. J., Pippard, M., Schaefer, R. M., & Winearls, C. G. (1997). Iron management in patients on rHuEpo. British Journal of Renal Medicine, 2, 6-8.

Sautois, B., Fillet, G., & Beguin, Y. (1997). Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Experimental Hematology, 25 (2), 103-8.

Cazzola, M., Ponchio, L., de Benedetti, F., Ravelli, A., Rosti, V., Beguin, Y., Invernizzi, R., Barosi, G., & Martini, A. (1996). Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood, 87 (11), 4824-30. doi:10.1182/blood.v87.11.4824.bloodjournal87114824

Cazzola, M., Ponchio, L., Pedrotti, C., Farina, G., Cerani, P., Lucotti, C., Novella, A., Rovati, A., Bergamaschi, G., & Beguin, Y. (1996). Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica, 81 (5), 434-41.

Hermanne, J.-P., TASSIN, F., Beguin, Y., & Fillet, G. (1996). Actualités thérapeutiques dans la thrombocytémie essentielle. Médecine et Hygiène, 54, 1487-1489.

Beguin, Y. (1995). Biology and clinical uses of erythropoietin in infants and children. International Journal of Pediatric Hematology/Oncology, 2, 457-470.

Martelli, M., Ponchio, L., Beguin, Y., Meloni, G., Mandelli, F., & Cazzola, M. (1994). Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica, 79 (5), 456-9.

Beguin, Y., Clemons, G. K., Pootrakul, P., & Fillet, G. (1993). Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood, 81 (4), 1067-76. doi:10.1182/blood.v81.4.1067.1067

Feron, C., Gothot, A., Grosdent, J.-C., Van Cauwenberge, J.-R., Schaaps, J.-P., Beguin, Y., & Paulus, J.-M. (1993). Purification, expansion, and multiple fluorochrome labeling of cord blood hemopoietic precursors: preliminary results. Journal of Hematotherapy, 2 (2), 259-61. doi:10.1089/scd.1.1993.2.259

Cazzola, M., Ponchio, L., Beguin, Y., Rosti, V., Bergamaschi, G., Liberato, N. L., Fregoni, V., Nalli, G., Barosi, G., & Ascari, E. (1992). Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood, 79 (1), 29-37. doi:10.1182/blood.v79.1.29.bloodjournal79129

Beguin, Y., Clemons, G. K., Oris, R., & Fillet, G. (1991). Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. Blood, 77 (4), 868-73. doi:10.1182/blood.v77.4.868.bloodjournal774868

Beguin, Y., Lipscei, G., Thoumsin, H., & Fillet, G. (1991). Blunted erythropoietin production and decreased erythropoiesis in early pregnancy. Blood, 78 (1), 89-93. doi:10.1182/blood.v78.1.89.89

Beguin, Y., Loo, M., & Fillet, G. (1991). Le dosage du récepteur circulant de la transferringe : une nouveauté pour quantifier l'érythropoïèse. Médecine et Hygiène, 49, 2041-2045.

Beguin, Y., Sautois, B., & Fillet, G. (1991). Perspectives diagnostiques et thérapeutiques de l'érythropoïétine. Médecine et Hygiène, 49, 2034-2045.

Andrien, F., Fassotte, M.-F., Beguin, Y., & Fillet, G. (1990). Traitement des lymphomes non hodgkiniens : de l'abstention thérapeutique à la greffe de moelle. Médecine et Hygiène, 48, 3672-3676.

Beguin, Y., Bours, V., Delbrouck, J.-M., Robaye, G., Roelandts, I., & Fillet, G. (1990). Relationship of serum selenium to tumor activity in acute non lymphocytic leukemia (ANLL) and chronic lymohocytic leukemia (CLL). Metal ions in Biology and Medecine, 500-502.

Beguin, Y., Bours, V., Delbrouck, J.-M., Robaye, G., Roelandts, I., Fillet, G., & Weber, G. (1990). Use of PIXE to measure serum copper, zinc, selenium, and bromine in patients with hematologic malignancies. Nuclear Instruments and Methods in Physics Research. Section B, Beam Interactions with Materials and Atoms, B49, 202-204. doi:10.1016/0168-583X(90)90243-N

Fassotte, M.-F., Beguin, Y., Andrien, F., & Fillet, G. (1990). Allogreffes et autogreffes de moelle osseuse. Indications, résultats, perspectives. Médecine et Hygiène, 48, 3666-3671.

Fillet, G., Baldelli, L., & BEGUIN, Y. (1989). Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood, 74 (2), 844-51. doi:10.1182/blood.v74.2.844.bloodjournal742844

Beguin, Y., Delbrouck, J.-M., Robaye, G., Roelandts, I., Bury, J., Fillet, G., & Weber, G. (1987). Correlation of serum trace elements with other biological parameters in hemoproliferative disorders. Trace element analytical chemistry in medicine and biology, 4, 537-545.

Andrien, F., Lemaire, M., Beguin, Y., Bury, J., Closon, J., David, J.-L., Dejardin-Closon, M.-T., Duvivier, A., Fillet, G., & Tjean, M. (1986). Second tumors and myeloproliferative diseases after Hodgkin's disease treatment. Leukemia Research, 10, 887.

Articles accepted in journal without peer reviewing

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology. doi:10.1371/journal.pone.0113764

Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology.

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2013). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 38.

Hannon, M., LECHANTEUR, C., Somja, J., Lucas, S., Belle, L., Bruck, F., Baudoux, E., Beguin, Y., Humblet-Baron, S., & Baron, F. (2013). Infusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 15.

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

MENTEN, C., Castermans, E., Hannon, M., Ormenese, S., Beguin, Y., & Baron, F. (2012). Evidence for Expansion of Host-derived CMV-specific CD8+ T cells after Allogeneic Transplantation with Non-Myeloablative Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Daulne, C., Willems, E., Gothot, A., Beguin, Y., & Baron, F. (2011). Comparison of Immune Reconstitution after Non-myeloablative Hematopoietic Cell Transplantation (HCT) with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 8.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (2011). Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 31.

Baron, F., & Beguin, Y. (2010). GVHD chronique et effet anti-tumoral. Correspondance en Onco-Hématologie, 5, 12-16.

Dresse, M.-F., & Beguin, Y. (2007). Haematopoietic stem cell transplantation for children in Belgium. Tijdschrift van de Belgische Kinderarts, 1, 44-51.

Beguin, Y., Loo, M., R'Zik, S., Sautois, B., & Fillet, G. (1994). Significance of soluble transferrin receptor. Molecular Biology of Hematopoiesis, 451-464.

Beguin, Y., & Fillet, G. (1991). Erythropoïétine : utilisation diagnostique et thérapeutique. Revue de l'Association Belge des Technologues de Laboratoire, 18 (3), 161-168.

Articles accepted in conference proceedings

Sid, S., LUTTERI, L., BEGUIN, Y., Louis, E., Beckers, A., & VALDES SOCIN, H. G. (2015). Familial thyrogastric autoimmune syndrome : a study of 22 kindreds. In Abstract book - 20th Annual Congress of the Belgian Society of Internal Medicine.

Posters for a doctoral (candidate, clinician-researcher) or postdoctoral (researcher) mandate

Farhat, K., Bodart, G., RENARD, J. D. C., Desmet, C., MOUTSCHEN, M., Beguin, Y., Baron, F., Salvatori, R., Geenen, V., & Martens, H. (23 May 2017). A surprising and dramatic neuroendocrine-immune phenotype of mice deficient in Growth Hormone-Releasing Hormone (GHRH). Poster session presented at European Congress of Endocrinology, Lisbonne, Portugal. doi:10.1530/endoabs.49.EP883

Farhat, K., Bodart, G., Renard, C., Desmet, C., MOUTSCHEN, M., BARON, F., Beguin, Y., Salvatori, R., Martens, H., & GEENEN, V. (May 2017). A surprising and dramatic neuroendocrine-immune phenotype of mice deficient in Growth Hormone-Releasing Hormone (GHRH). Poster session presented at The 19th European Congress of Endocrinology, Lisbon, Portugal.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma. Poster session presented at 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology. Poster session presented at 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Fransolet, G., Ehx, G., SOMJA, J., Belle, L., Drion, P., Humblet-Baron, S., Beguin, Y., & Baron, F. (30 January 2015). Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease. Poster session presented at 30th general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., SQUIFFLET, J.-P., Honoré, P., DELVENNE, P., MEURISSE, M., BAUDOUX, E., & BEGUIN, Y. (30 May 2013). INFUSION OF THIRD-PARTY MESENCHYMAL STEM CELLS (MSC) AFTER KIDNEY AND LIVER TRANSPLANTATION: A PHASE I-II, OPEN-LABEL, CLINICAL STUDY (EudraCT 2011-001822-81 & NCT01429038). Poster session presented at 13eme rencontre de Beaune, Beaune, France.

Bonnet, C., MENTEN, C., LAMBERT, F., Gothot, A., Baron, F., CAERS, J., HERENS, C., & Beguin, Y. (25 January 2013). Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones. Poster session presented at BHS, General Annual Meeting.

HAFRAOUI, K., CAERS, J., TASSIN, F., & Beguin, Y. (2013). Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide. Poster session presented at BHS 28th General Annual Meeting, Gent, Belgium.

Belle, L., Bruck, F., FOGUENNE, J., GOTHOT, A., BEGUIN, Y., BARON, F., & BRIQUET, A. (2012). Imatinib and Nilotinib do not prevent adhesion and migration of human CD34+ in vitro and in immunodeficient mice. Poster session presented at Belgian Hematological Society Annual Meeting.

Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease. Poster session presented at Belgian Hematological Society General Annual Meeting.

Bruck, F., Baron, F., DUBOIS, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., Beguin, Y., & Humblet-Baron, S. (February 2011). Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells. Poster session presented at ASBMT meeting 2011. doi:10.1016/j.bbmt.2010.12.535

Belle, L., Baron, F., Bruck, F., Hannon, M., Servais, S., Beguin, Y., & BRIQUET, A. (2011). Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice. Poster session presented at 26th General Meeting of the Belgian Hematological Society.

Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells. Poster session presented at Belgian Hematological Society Annual General Meeting.

Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells. Poster session presented at ASBMT 2011.

Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation. Poster session presented at 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium.

Bonnet, C., Beguin, Y., FASSOTTE, M.-F., & Fillet, G. (2006). Limited usefulness of CA 125 measurement in the management of hodgkin's and non-hodgkin's lymphomas. Poster session presented at 21st General Meeting of the Belgian Hematological Society.